Introduction
Peripheral artery disease (PAD) is estimated to affect up to 29% of people 50 years of age in the US 1 and over 200 million people worldwide. 2 Diagnosis of PAD is associated with an increased risk of adverse medical events and premature mortality from cardiovascular disease. 3, 4 The classic symptom of PAD, intermittent claudication (IC), is characterized by exertional leg pain that resolves with rest and is estimated to affect up to 35% of PAD patients 50 years of age and older. 5, 6 Patients with PAD and IC have impaired walking ability and poor functional outcomes as well as a reduced quality of life due at least in part to the leg pain experienced. 7 Thus, PAD with IC is a significant international healthcare concern with adverse impact on patients resulting from the systemic atherosclerosis and the symptom of IC. There are few pharmacological therapy options available to treat PAD symptoms. The most efficacious option currently to improve IC is supervised walking exercise. However, this treatment is not widely available despite the strong evidence of its efficacy. In contrast, options that are more readily available to provide symptom relief for IC include invasive treatments such as endovascular therapy and surgical procedures. 8 In this issue of Circulation, Nordanstig and colleagues 9 present their results comparing invasive vs. non-invasive treatments in a prospective, single-center randomized clinical trial in patients with stable IC symptoms. The aim of the Invasive Revascularization Or Not in Intermittent Claudication (IRONIC) trial was to compare outcomes for PAD patients receiving peripheral revascularization in combination with non-invasive therapy to outcomes in patients who only received non-invasive medical therapy. The non-invasive therapy included the provision of educational materials and medical management of the systemic atherosclerosis, prescription of cilostazol (100 mg twice daily), and general advice to walk at least 30 minutes at patients resulting from the systemic atherosclerosis and the symptom of IC. The ere re e a a are r f f few w ew pharmacological therapy options available to treat PAD symptoms. The most efficacious option cu urr rr ren en entl tl tly y to to to i i im mp mpro ro rov ve ve IC is supervised walking exe xe x r rc cise. However r, , this s tr tr tre e eatment is not widely av vai ai ila l ble desp pit ite e e th h he e st s stro o ong ng ng e e evi vi vide denc nc nce e o of of i its e e eff f ficac c cy y. . In n n c co cont nt tra a ast st, op p pti tion on ns th that at at a a are re m m mor or re e re re r ad ad adil l ily y av vai ai aila la abl bl b e e to to o p p pro rov v vid de de s sym ym ympt ptom m m r rel el elie ie ief f f fo for r r IC IC IC i i inc nc ncl l lud ud ude e i in inv va vasi si sive ve ve tre re reat at tme me ment nt n s s su u uch ch h a as s s en en ndo do dova asc scul ul u ar ar r herapy and su su urg rg rgic ic cal al al p p pro ro roce edu du dure r r s. s. s. least 3 times per week with use of Nordic poles being encouraged. The exercise program was reinforced at 3 and 6 months. A key point of difference from other trials was that the primary outcome of the IRONIC trial was health-related quality of life (HRQOL) rather than treadmill walking ability or other objective measurements which have often been used as primary outcomes in prior trials for PAD with IC patients. The primary endpoint was assessed pre and post 1-year of treatment using two well-validated HRQOL questionnaires. 10, 11 The results were positive, demonstrating greater improvements in HRQOL in the patients treated with invasive therapy than the non-invasive therapy alone. In thinking about the IRONIC trial, two key points of discussion arise which have implications for future directions in research for PAD patients with IC.
Quality of Life as a Primary Outcome in PAD with IC
The IRONIC trial used several innovative elements in the study design. Prominent among them was the use of HRQOL as the primary endpoint. The use of patient-reported outcomes as a primary endpoint in a clinical trial raises some questions that must be addressed, however.
Whether HRQOL is the correct primary endpoint for a study largely depends on the goals of the study and the lens through which the results will be viewed. 12 Most peripheral revascularization trials have utilized primary outcomes such as loss of primary patency, and need for reintervention rather than patient-reported outcomes specifically. 13 Exercise training studies in PAD have most often used treadmill walking time or distance as the primary outcome.
Perception of an objective measure such as a change in hemodynamics may be of great importance to the investigator or to a clinician, given its relationship to IC symptoms. However, a patient may judge the benefit of an intervention by effects on HRQOL, which is composed of many dimensions and not just leg symptoms. 14, 15 The concept of HRQOL as a primary outcome with IC.
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Lack of Easy Access to Exercise Training for PAD with IC
In addition to the question of the usefulness of HRQOL as a primary endpoint, results of the IRONIC trial highlighted an already well-known area of weakness in the treatment of PAD with IC-the relative dearth of effective non-invasive treatments for IC. Only one drug, cilostazol, has been approved by the Food and Drug Administration as an effective treatment for IC. However, it is less efficacious than supervised walking exercise and is contraindicated in patients with heart failure. Supervised walking exercise to improve walking in those with IC has been rated IA by the ACC/AHA guidelines for the treatment of IC in PAD. There is an abundance of evidence to support this conclusion. 8, 20 However, supervised exercise continues to be largely unavailable to most patients, as is pointed out by the authors of the IRONIC trial. 9 Many issues have precluded the widespread use of this efficacious therapy. Likely factors include the lack of thirdmetrics have not been implemented on a consistent basis in clinical settings. 19 A Ad dd ddit it itio iona na nall ll lly, y, y, t th he use and interpretation of the most appropriate aspects of HRQOL are important for determining h he e be be best st st t t tre re reat at atm m ment nt nt o opt p ions in PAD.
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Call for Research
The results of the IRONIC trial add to the existing knowledge base regarding revascularization as a treatment which clearly can improve blood flow and thereby reduce IC. 24 In addition, the IRONIC trial raises some important questions that can point to important research directions in vascular medicine. Invasive procedures lead to improved patient satisfaction and better walking performance outcomes when compared to a non-invasive medical therapeutic approach including general exercise advice. So what is wrong with non-invasive therapy options, specifically exercise training for PAD? The CLaudication: Exercise Vs. Endoluminal Revascularization (CLEVER) study did use supervised exercise training as a comparator to invasive therapy with proven to be more successful. 22, 23 The reason for the success of these trials may b b be th th t at at at s s som om ome e e elements of supervised exercise programs were included such as training, monitoring and co oac ac achi hi hin ng ng f f for or o p pat tie ie ien nt nts. Including some of the suc c cce ce c s ss sful parts of s sup up u er rvi vi vis s se e ed walking training in h h he co c mmunit ty y s set tt tin ng g g ma ma may y be be be t the he e ap ap app pr ro op pria a ate e e nex xt xt ste ep p p fo for r r n no on-n--in inva asi si ive ve ve t the he er ra apy py t t tha ha hat t in in i cl cl clud ud udes es s ex xer er erci ci cise se s t tra ra ain in inin ing g g a as s a a w wa ay ay to o im im impr pr prov ov ove e ou ou outc tc tcom om omes es es. .
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